QuickView: Upcoming Omidria catalysts
The FDA’s approval of Omeros’s Omidria on 30 May for use during cataract surgery or lens replacement will start the US launch process in late summer/early autumn of 2014. Pricing is to be disclosed before launch while EU approval is expected later in 2014. Anticipation of a good price point at launch and EU approval (with potential for an EU partnering deal) would maintain momentum through 2014. In the longer term, Omeros needs to establish Omidria in a fragmented market by educating surgeons about the benefits of the product.Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. The company's drug product OMIDRIA? is marketed in the U.S. for use during cataract surgery or intraocular lens replacement. In its pipeline the company has clinical-stage development programs focused on: complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; and addictive and compulsive disorders.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.